2002 Press Releases Communiqués de presse

October 29, 2002 29 October, 2002

PSC Fertility Monitor Success Story Profile The First In A Series

September 25, 2002 25 September, 2002

FDA Approves Pheromone Sciences' PSC Fertility Monitor

August 16, 2002 16 August, 2002

Pheromone Sciences Corp. Completes Private Placement Offering

June 17, 2002 17 June, 2002

UK's Largest Healthcare Retailer to Distribute Pheromone's Fertility Monitor

June 11, 2002 11 June, 2002

Pheromone Sciences' Successfully Completes Dairy Cow Monitoring Study

March 13, 2002 13 March, 2002

Pheromone Sciences Files with FDA for Marketing Approval of its Fertility Monitor

February 28, 2002 28 February, 2002

Pheromone Sciences Corp. Announces Annual and Special Meeting

February 12, 2002 12 February, 2002

Pheromone Sciences Corp Reports Positive Trial Results on Fertility Monitor

January 15, 2002 15 January, 2002

Pheromone Sciences Corp. Completes Private Placement Offering

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 29, 2002 29 October, 2002

PSC Fertility Monitor Success Story Profile The First In A Series


Pheromone Sciences Corp (TSX:PHS), is pleased to announce a Toronto based Success Story about a pregnancy resulting from the use of the PSC Fertility Monitor as a timing aid in identifying the conception or fertility window.

The Brenda and Marcus Story as reported to Pheromone Sciences: "As a couple we lead a very active life. Marcus is a marathon runner and is frequently out training for hours each evening. I am 36 years old and also work full- time. We are a very active family, always enjoying the outdoors and participating in our daughter's life fully.

In November 2001, Marcus and I decided to try and conceive a second child. Everyone mentioned to us that it would take only a month or two since we had previously had a child. After six months had passed by, my doctor was becoming concerned about my age and an irregular and long menstrual cycle (39 days) and the possible factor that as Marcus is an avid marathon runner, there might be some impact on his sperm count. He mentioned that our chances for a conception seemed slim without the use of fertility drugs. We decided at the time not to turn to the fertility drugs and allow nature to take its course.

A friend mentioned the new Fertility Monitor product from Pheromone Sciences. As it seemed very easy and simple to use, I decided to give it a try. The watch-like monitor allowed me to continue a normal life without the use of medications or any methods of ovulation detection. I set up the monitor (watch) to coincide with my menstrual cycle and began wearing it as soon as my monthly cycle began in order to determine the most fertile time in my cycle. I wore the watch every night until it told me when my most fertile six days were. The rest is history.

Within the first month of using the PSC Fertility Monitor I became pregnant. I am due this coming March. The fact that I could easily slip the watch on every night without being concerned about trying to take and interpret basal body temperatures each morning or using the very expensive and inconvenient LH test strips (I tried all these to no avail) made my life and my family's so much better and less stressful. I was able to concentrate on other aspects of my life and not worry about the fertile days in my cycle. The watch was able to help us achieve our conception goal by identifying the complete 6 days of the fertility window for us.

I would recommend the PSC Fertility Monitor to anyone who is trying to conceive." said Brenda.

"We are very happy to pass on knowledge of Brenda's and Marcus' success in achieving their conception goals by using our product, the PSC Fertility Monitor", said Christopher Neuman, President and CEO of Pheromone Sciences. "We welcome the news from others who have had or will have a similar experience."

Since the FDA product approval was announced, Pheromone Sciences has opened the site www.fertiliteov.com for couples seeking to purchase this new product.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 25, 2002 25 September, 2002

FDA Approves Pheromone Sciences' PSC Fertility Monitor


Toronto, Ontario (September 25, 2002) - Pheromone Sciences Corp (TSX Venture Exchange: PHS), today announced that it has received FDA approval for its PSC Fertility Monitor(tm). The approval permits PHS to commence marketing and distribution activities throughout the United States under the indicated use of Fertility and Ovulation Prediction, thus enhancing effective decision making in family planning. No other commercially available ovulation-monitoring device provides as much advanced notice of ovulation.

The PSC Fertility Monitor is a watch like fertility cycle monitoring device for the consumer and professional medical market. The PSC Fertility Monitor looks to set a new benchmark in providing a reliable "predictive" approach to natural, cycle-based family planning through the measurement of perspiration ion changes on the surface of the skin. These changes in female perspiration allow for the prediction of ovulation up to 4 days prior to the day of ovulation without the need for inconvenient urine or blood testing.

Following the release of U.S. clinical trial results earlier this year, Dr. Arthur Haney, Professor of Obstetrics and Gynecology of Duke University commented that, "Couples trying to conceive and using the PSC Fertility Monitor will be able to predict their ovulation date 4 days in advance for the first time and have the advantage of identifying the 6 days of maximum fertility: the 4 days before, the day of and the day after ovulation. This allows the couple to reduce the stress involved and with intercourse on multiple days, increase their cumulative likelihood of pregnancy."

Currently, the North American market for fertility related products is valued at about US$450 million and forecast to grow to in excess of US$560 million by 2007."We are confident that the consumer uptake of our product will be very encouraging", said Christopher Neuman, President and CEO of Pheromone Sciences Corp. "With this important milestone achieved, our attention will be focused on generating revenue for the Company".

A specific web site www.fertiliteOV.com has been created for the monitor where couples can access specific information about the product offering.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 16, 2002 16 August, 2002

Pheromone Sciences Corp. Completes Private Placement Offering


Toronto, Ontario -- August 16, 2002 -- Pheromone Sciences Corp. (TSXVenture Exchange:PHS) today announced that it has completed a private placement, of 1,300,000 units of the Company at an issue price of $0.25 per unit for gross proceeds of $325,000. Each unit will be exercisable, at no additional consideration, into one common share of the Company and one common share purchase warrant. Each common share purchase warrant has a term of 12 months and will be exercisable into one common share at an exercise price of $0.30 per share.

Proceeds of the offering will be used to support the Company's research and development program, ongoing operations, and business development.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 17, 2002 17 June, 2002

UK's Largest Healthcare Retailer to Distribute Pheromone's Fertility Monitor


Pheromone Sciences Signs First Commercialization Agreement

Toronto, Ontario (June 17, 2002) -- Pheromone Sciences Corp. (TSX Venture Exchange:PHS), a Toronto- based biotech R & D company with proprietary technology in the field of non-invasive fertility and ovulation detection and Tri-Vision International Ltd./Lt�©e (TSX:TVL), a consumer electronics and marketing company with special retail relationships across the UK are pleased to announce the signing of a Letter of Intent (LOI) for the distribution of Pheromone's PSC Fertility Monitor(tm) in the United Kingdom. The LOI is expected to be followed by a definitive Distribution Agreement. The distribution agreement is to provide for the sale of the PSC Fertility Monitor exclusively in Boots Company PLC across the United Kingdom over a three-year period.

Boots is the UK's largest retailer of health products in the United Kingdom with over 1,400 retail outlets and a strong Internet based pharmacy network. Under the proposed distribution agreement Boots would be committed to selling a significant number of units of the product during each year. The product is expected to be available in Boots outlets before year-end.

The PSC Fertility Monitor is a fertility cycle monitoring device for the consumer and professional medical market. The PSC Fertility Monitor looks to set a new benchmark in providing a reliable "predictive" approach to natural, cycle-based family planning. The PSC Fertility Monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio-sensing and computer technologies. These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

As demonstrated in the recent US trial, the PSC Fertility Monitor detected more days of the conception window (the days when sexual intercourse can lead to a pregnancy) than the LH test strip product or the basal body temperature method. This determination, coupled with the published literature on the chances of conception during this window strongly suggests that women who use the PSC Fertility Monitor as a means of identifying their fertile window to time intercourse, can expect a substantially higher probability of conception or a substantially shorter time to pregnancy than if they relied solely on home based LH test kits as a means to time intercourse.

"The signing of this "LOI" represents a significant step in the execution of our commercialization strategy, stated Christopher Neuman", President and CEO of Pheromone. "Much effort has been put into the development of our Fertility Monitor technology and this solid expression of interest from one of the world's leading health care retailing organizations is a validation of our efforts to bring this technology to couples around the world."

This business agreement is the first for Tri- Vision's newly established Tri-Vision Technologies International Inc. subsidiary, which was created for the development and marketing of innovative technologies.

"While this is our first endeavor in delivering new technologies for other companies, our core business has been operating internationally for years and we continue to show success with our V-chip licensing to internationally-based television manufacturers. This relationship with Pheromone and Boots is a clear demonstration of Tri-Vision Technologies ability to market internationally." stated Tri-Vision Technologies President Toshginori Ikebe.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and do not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 11, 2002 11 June, 2002

Pheromone Sciences' Successfully Completes Dairy Cow Monitoring Study


Pheromone Sciences Corp (CDNX: PHS), today announced that it has completed the preliminary feasibility trial of its large animal fertility and ovulation detection technology for large animal breeding at the Ontario Veterinary College under the direction of Dr. Walter H. Johnson DVM, MVSc, Dipl. ACT, Professor of Theriogenology at the University of Guelph.

The study was successful in detecting hormone- related changes indicative of heat in the majority of the dairy cows tested confirming the Company's ability to adapt its proprietary PSC Fertility Monitor technology to the specific physiology and living environment of the dairy cow. In doing so the Company intends to pursue further development of this product to predict impending estrus.

"We are very pleased that after many months of working together with the scientific staff of Pheromone Sciences, we are able to move this project to the next stage of development toward creating a new technology that will be of significant benefit to dairy farmers at large", commented Dr. Johnson, he continued, "A product that can increase conception rates in dairy herd breeding would positively impact productivity on dairy farms across North America".

Dairy industry researchers estimate that within the North American dairy industry U.S. producers incur revenue losses directly attributable to inefficient herd reproduction management of approx. US$400 million per annum. The ability to provide accurate monitoring of the fertility status of commercial livestock would afford a significant commercial opportunity for both the agricultural community and Pheromone Sciences Corp.

"Results using our new sensor configuration have us quite excited," said Doug Marett, Pheromone Sciences Chief Scientific Officer. "We will now look to optimize the best location and mounting method for the device building sufficient data to generate algorithms to predict impending heat for the dairy cow."

Christopher Neuman, President and CEO of Pheromone Sciences Corp. said, "We are very excited about the progress we have made in extending our sensor and reporting technology into a new application with such huge commercial applications."

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 13, 2002 13 March, 2002

Pheromone Sciences Files with FDA for Marketing Approval of its Fertility Monitor


Pheromone Sciences (PHS:CDNX) today announced that it has filed a 510K application with the United States Food and Drug Administration seeking U.S. marketing approval for its lead product, the PSC Fertility Monitor(tm).

This application follows the recent announcement of positive results from a U.S. based multi-center clinical trial carried out at Duke University in Durham, N.C. under the direction of Dr. Arthur Haney and at The Women's Institute for Fertility, Endocrinology and Menopause affiliated with the Thomas Jefferson University Medical School in Philadelphia, PA., supervised by Dr. Stephen Corson.

Approval by the FDA of the Pheromone Sciences application would enable the Company to market the PSC Fertility Monitor(tm) across North America as well as in various other countries that use FDA guidelines as the primary element in granting marketing approvals. It is anticipated that a response to the Company's application will be received this summer.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Contact: Lorne Woods Judson Woods (800) 937-3095 lorne@judsonwoods.com 443 King Street East investor@pheromonesciences.com www.pheromonesciences.com

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 28, 2002 28 February, 2002

Pheromone Sciences Corp. Announces Annual and Special Meeting


Pheromone Sciences Corp. (CDNX:PHS) today announced that its Annual and a Special Meeting of shareholders will be held at The Toronto Stock Exchange Conference Centre, 130 King Street West, Toronto, Ontario, M5X 1J2, commencing at 4:30 p.m. (E.S.T.) on Wednesday, April 10th, 2002. March 7, 2002 has been set as the record date for determining those shareholders entitled to receive notice of the meeting and to vote at the meeting.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Investor Contact:

Lorne Woods 1(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 12, 2002 12 February, 2002

Pheromone Sciences Corp Reports Positive Trial Results on Fertility Monitor


Pheromone Sciences Corp (CDNX: PHS), is pleased to announce that it has received positive results from its PSC Fertility Monitor�¢ï¿½�¢ U.S. clinical trial.

The trial, which enrolled 105 subjects, was carried out at Duke University, Durham, N.C., under the direction of Dr. A. Haney Professor of Obstetrics and Gynecology of Duke University and Dr. Stephen Corson Professor, Obstetrics and Gynecology at The Women's Institute of Fertility, Sterility and Menopause, Thomas Jefferson University Medical School in Philadelphia. Results showed that 73% of the ovulatory women had their ovulation date correctly predicted to within +/-2 days of the ovulation date determined by blood serum levels. These results are consistent with those previously reported (76%) from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto.

As expected, due to the product's non-invasive nature, no safety or side effects issues were reported throughout the trial.

Based on these results, the Company will, within 30 days, file a 510K submission to the FDA for marketing approval of the Fertility Monitor in the United States.

It is well recognized by the medical community that conception occurs when sexual intercourse occurs within a 6 day period starting approximately four to five days before ovulation. The PSC Fertility Monitor confirmed its unique ability to predict a women's fertility window. Discreetly housed within a wristwatch-like device that is worn during sleeping hours, the PSC Fertility Monitor offers women an easy to use, non-invasive means of obtaining advance notice of their fertility window.

"Based upon the data analysis of the patients who completed the trial, the PSC Fertility Monitor detected more days of the conception window (the days when sexual intercourse can lead to a pregnancy) than the LH test strip product. This determination, coupled with the published literature on the chances of conception during this window (Wilcox, New England Journal of Medicine), strongly suggests that women who use the PSC Fertility Monitor as a means of identifying their fertile window to time intercourse, can expect a substantially higher probability of conception or a substantially shorter time to pregnancy than if they relied solely on home based LH test kits as a means to time intercourse," said Dr. A. Haney, Professor of Obstetrics and Gynecology of Duke University. "This is based upon the PSC Fertility Monitor's unique ability to identify the 6 day fertility window with up to a four day advance notice of the predicted ovulation day. For women who are seeking to become pregnant, the PSC Fertility Monitor would seem to offer some unique advantages in helping these women to discover their entire fertility window."

As a non-invasive device designed for in-home testing to identify the complete fertility window without the inconvenient and unpleasant use of urine or blood samples, the PSC Fertility Monitor offers a new level of convenience, ease of use and the knowledge that the entire fertility window is now easily identified," said Dr. Stephen Corson, Professor, Obstetrics and Gynecology at The Women's Institute of Fertility, Sterility and Menopause, Thomas Jefferson University Medical School in Philadelphia.

"Providing the ability to utilize more of the fertility window is an element that will aid women wishing to conceive", said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "Combining advance notice along with convenience and ease of use, make this a product we believe women will embrace".

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT

Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 15, 2002 15 January, 2002

Pheromone Sciences Corp. Completes Private Placement Offering


Pheromone Sciences Corp. (CDNX:PHS) today announced that it has completed the sale, via private placement, of 410,000 special warrants of the Company at an issue price of $0.55 per special warrant for gross proceeds of $225,500. Each special warrant will be exercisable, at no additional consideration, into one common share of the Company and one common share purchase warrant. Each warrant has a term of 18 months and will be exercisable into one common share of an exercise of $0.70 per share.

Proceeds of the offering will be used to support the Company's research and development program, ongoing operations, and business development.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

INVESTOR CONTACT

Lorne Woods (800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com



Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.